1
|
Rimbert S, Moreira JB, Xapelli S, Lévi S. Role of purines in brain development, from neuronal proliferation to synaptic refinement. Neuropharmacology 2023:109640. [PMID: 37348675 DOI: 10.1016/j.neuropharm.2023.109640] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Revised: 06/15/2023] [Accepted: 06/19/2023] [Indexed: 06/24/2023]
Abstract
The purinergic system includes P1 and P2 receptors, which are activated by ATP and its metabolites. They are expressed in adult neuronal and glial cells and are crucial in brain function, including neuromodulation and neuronal signaling. As P1 and P2 receptors are expressed throughout embryogenesis and development, purinergic signaling also has an important role in the development of the peripheral and central nervous system. In this review, we present the expression pattern and activity of purinergic receptors and of their signaling pathways during embryonic and postnatal development of the nervous system. In particular, we review the involvement of the purinergic signaling in all the crucial steps of brain development i.e. in neural stem cell proliferation, neuronal differentiation and migration as well as in astrogliogenesis and oligodendrogenesis. Then, we review data showing a crucial role of the ATP and adenosine signaling pathways in the formation of the peripheral neuromuscular junction and of central GABAergic and glutamatergic synapses. Finally, we examine the consequences of deregulation of the purinergic system during development and discuss the therapeutic potential of targeting it at adult stage in diseases with reactivation of the ATP and adenosine pathway.
Collapse
Affiliation(s)
- Solen Rimbert
- INSERM UMR-S 1270, Sorbonne Université, Institut du Fer à Moulin, 75005, Paris, France
| | - João B Moreira
- INSERM UMR-S 1270, Sorbonne Université, Institut du Fer à Moulin, 75005, Paris, France; Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Instituto de Medicina Molecular - João Lobo Antunes (iMM - JLA), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Sara Xapelli
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Instituto de Medicina Molecular - João Lobo Antunes (iMM - JLA), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Sabine Lévi
- INSERM UMR-S 1270, Sorbonne Université, Institut du Fer à Moulin, 75005, Paris, France.
| |
Collapse
|
2
|
Lanuza MA, Tomàs J, Garcia N, Cilleros-Mañé V, Just-Borràs L, Tomàs M. Axonal competition and synapse elimination during neuromuscular junction development. CURRENT OPINION IN PHYSIOLOGY 2018. [DOI: 10.1016/j.cophys.2018.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
3
|
Naviaux RK, Curtis B, Li K, Naviaux JC, Bright AT, Reiner GE, Westerfield M, Goh S, Alaynick WA, Wang L, Capparelli EV, Adams C, Sun J, Jain S, He F, Arellano DA, Mash LE, Chukoskie L, Lincoln A, Townsend J. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol 2017; 4:491-505. [PMID: 28695149 PMCID: PMC5497533 DOI: 10.1002/acn3.424] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Revised: 04/18/2017] [Accepted: 04/20/2017] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVE No drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low-dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment-1 (SAT-1) trial was a double-blind, placebo-controlled, translational pilot study to examine the safety and activity of low-dose suramin in children with ASD. METHODS Ten male subjects with ASD, ages 5-14 years, were matched by age, IQ, and autism severity into five pairs, then randomized to receive a single, intravenous infusion of suramin (20 mg/kg) or saline. The primary outcomes were ADOS-2 comparison scores and Expressive One-Word Picture Vocabulary Test (EOWPVT). Secondary outcomes were the aberrant behavior checklist, autism treatment evaluation checklist, repetitive behavior questionnaire, and clinical global impression questionnaire. RESULTS Blood levels of suramin were 12 ± 1.5 μmol/L (mean ± SD) at 2 days and 1.5 ± 0.5 μmol/L after 6 weeks. The terminal half-life was 14.7 ± 0.7 days. A self-limited, asymptomatic rash was seen, but there were no serious adverse events. ADOS-2 comparison scores improved by -1.6 ± 0.55 points (n = 5; 95% CI = -2.3 to -0.9; Cohen's d = 2.9; P = 0.0028) in the suramin group and did not change in the placebo group. EOWPVT scores did not change. Secondary outcomes also showed improvements in language, social interaction, and decreased restricted or repetitive behaviors. INTERPRETATION The safety and activity of low-dose suramin showed promise as a novel approach to treatment of ASD in this small study.
Collapse
Affiliation(s)
- Robert K. Naviaux
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of MedicineUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of PediatricsUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of PathologyUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
| | - Brooke Curtis
- Alliant International University10455 Pomerado RoadSan DiegoCalifornia92131
| | - Kefeng Li
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of MedicineUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
| | - Jane C. Naviaux
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of NeurosciencesUniversity of CaliforniaSan Diego School of Medicine9500 Gilman Drive.La JollaCA92093‐0662
| | - A. Taylor Bright
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of MedicineUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
| | - Gail E. Reiner
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of NeurosciencesUniversity of CaliforniaSan Diego School of Medicine9500 Gilman Drive.La JollaCA92093‐0662
| | - Marissa Westerfield
- The Research in Autism and Development Laboratory (RAD Lab)University of California9500 Gilman DriveLa JollaCA92093‐0959
| | - Suzanne Goh
- Pediatric Neurology Therapeutics7090 Miratech DrSan DiegoCA92121
| | - William A. Alaynick
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of MedicineUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
| | - Lin Wang
- The Mitochondrial and Metabolic Disease CenterUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
- Department of MedicineUniversity of CaliforniaSan Diego School of Medicine214 Dickinson St., Bldg CTF, Rm C102San Diego92103‐8467California
| | - Edmund V. Capparelli
- Department of Pediatricsand Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of CaliforniaSan Diego School of Medicine9500 Gilman DriveLa JollaCA92093‐0657
| | - Cynthia Adams
- Clinical and Translational Research Institute (CTRI)University of CaliforniaSan DiegoLa JollaCA92037
| | - Ji Sun
- Clinical and Translational Research Institute (CTRI)University of CaliforniaSan DiegoLa JollaCA92037
| | - Sonia Jain
- Department of Family Medicine and Public HealthUniversity of CaliforniaSan DiegoLa JollaCA92093
| | - Feng He
- Department of Family Medicine and Public HealthUniversity of CaliforniaSan DiegoLa JollaCA92093
| | - Deyna A. Arellano
- Clinical and Translational Research Institute (CTRI)University of CaliforniaSan DiegoLa JollaCA92037
| | - Lisa E. Mash
- The Research in Autism and Development Laboratory (RAD Lab)University of California9500 Gilman DriveLa JollaCA92093‐0959
- Department of PsychologySan Diego State University5500 Campanile DriveSan DiegoCA92182
| | - Leanne Chukoskie
- The Research in Autism and Development Laboratory (RAD Lab)University of California9500 Gilman DriveLa JollaCA92093‐0959
- Institute for Neural ComputationUniversity of California9500 Gilman DriveLa Jolla92093‐0523
| | - Alan Lincoln
- Alliant International University10455 Pomerado RoadSan DiegoCalifornia92131
| | - Jeanne Townsend
- Department of NeurosciencesUniversity of CaliforniaSan Diego School of Medicine9500 Gilman Drive.La JollaCA92093‐0662
- The Research in Autism and Development Laboratory (RAD Lab)University of California9500 Gilman DriveLa JollaCA92093‐0959
| |
Collapse
|
4
|
Burnstock G, Arnett TR, Orriss IR. Purinergic signalling in the musculoskeletal system. Purinergic Signal 2013; 9:541-72. [PMID: 23943493 PMCID: PMC3889393 DOI: 10.1007/s11302-013-9381-4] [Citation(s) in RCA: 93] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 07/12/2013] [Indexed: 12/11/2022] Open
Abstract
It is now widely recognised that extracellular nucleotides, signalling via purinergic receptors, participate in numerous biological processes in most tissues. It has become evident that extracellular nucleotides have significant regulatory effects in the musculoskeletal system. In early development, ATP released from motor nerves along with acetylcholine acts as a cotransmitter in neuromuscular transmission; in mature animals, ATP functions as a neuromodulator. Purinergic receptors expressed by skeletal muscle and satellite cells play important pathophysiological roles in their development or repair. In many cell types, expression of purinergic receptors is often dependent on differentiation. For example, sequential expression of P2X5, P2Y1 and P2X2 receptors occurs during muscle regeneration in the mdx model of muscular dystrophy. In bone and cartilage cells, the functional effects of purinergic signalling appear to be largely negative. ATP stimulates the formation and activation of osteoclasts, the bone-destroying cells. Another role appears to be as a potent local inhibitor of mineralisation. In osteoblasts, the bone-forming cells, ATP acts via P2 receptors to limit bone mineralisation by inhibiting alkaline phosphatase expression and activity. Extracellular ATP additionally exerts significant effects on mineralisation via its hydrolysis product, pyrophosphate. Evidence now suggests that purinergic signalling is potentially important in several bone and joint disorders including osteoporosis, rheumatoid arthritis and cancers. Strategies for future musculoskeletal therapies might involve modulation of purinergic receptor function or of the ecto-nucleotidases responsible for ATP breakdown or ATP transport inhibitors.
Collapse
Affiliation(s)
- Geoffrey Burnstock
- Autonomic Neuroscience Centre, University College Medical School, Rowland Hill Street, London, NW3 2PF, UK,
| | | | | |
Collapse
|
5
|
Valladares D, Almarza G, Contreras A, Pavez M, Buvinic S, Jaimovich E, Casas M. Electrical stimuli are anti-apoptotic in skeletal muscle via extracellular ATP. Alteration of this signal in Mdx mice is a likely cause of dystrophy. PLoS One 2013; 8:e75340. [PMID: 24282497 PMCID: PMC3839923 DOI: 10.1371/journal.pone.0075340] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Accepted: 08/11/2013] [Indexed: 12/20/2022] Open
Abstract
ATP signaling has been shown to regulate gene expression in skeletal muscle and to be altered in models of muscular dystrophy. We have previously shown that in normal muscle fibers, ATP released through Pannexin1 (Panx1) channels after electrical stimulation plays a role in activating some signaling pathways related to gene expression. We searched for a possible role of ATP signaling in the dystrophy phenotype. We used muscle fibers from flexor digitorum brevis isolated from normal and mdx mice. We demonstrated that low frequency electrical stimulation has an anti-apoptotic effect in normal muscle fibers repressing the expression of Bax, Bim and PUMA. Addition of exogenous ATP to the medium has a similar effect. In dystrophic fibers, the basal levels of extracellular ATP were higher compared to normal fibers, but unlike control fibers, they do not present any ATP release after low frequency electrical stimulation, suggesting an uncoupling between electrical stimulation and ATP release in this condition. Elevated levels of Panx1 and decreased levels of Cav1.1 (dihydropyridine receptors) were found in triads fractions prepared from mdx muscles. Moreover, decreased immunoprecipitation of Cav1.1 and Panx1, suggest uncoupling of the signaling machinery. Importantly, in dystrophic fibers, exogenous ATP was pro-apoptotic, inducing the transcription of Bax, Bim and PUMA and increasing the levels of activated Bax and cytosolic cytochrome c. These evidence points to an involvement of the ATP pathway in the activation of mechanisms related with cell death in muscular dystrophy, opening new perspectives towards possible targets for pharmacological therapies.
Collapse
Affiliation(s)
- Denisse Valladares
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Gonzalo Almarza
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Ariel Contreras
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Mario Pavez
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Sonja Buvinic
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
- Departamento de Ciencias Básicas y Comunitarias, Facultad de Odontología, Universidad de Chile, Santiago, Chile
| | - Enrique Jaimovich
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Mariana Casas
- Centro de Estudios Moleculares de la Célula, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
- Programa de Fisiología y Biofísica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
- * E-mail:
| |
Collapse
|
6
|
Purine P2Y receptors in ATP-mediated regulation of non-quantal acetylcholine release from motor nerve endings of rat diaphragm. Neurosci Res 2011; 71:219-25. [PMID: 21821069 DOI: 10.1016/j.neures.2011.07.1829] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2011] [Revised: 07/15/2011] [Accepted: 07/21/2011] [Indexed: 11/22/2022]
Abstract
We established the effect of ATP, which is released together with acetylcholine (ACh), on the non-quantal ACh release (NQR) in rat diaphragm endplates and checked what kind of purine receptors are involved. NQR was estimated by the amplitude of endplate hyperpolarization (the H-effect) following the blockade of postsynaptic nicotinic receptors and cholinesterase. 100 μM ATP reduced the H-effect to 66% of the control. The action of ATP remained unchanged after the inhibition of ionotropic P2X receptors by Evans blue and PPADS, but disappeared after the application of the broad spectrum P2 receptor antagonist suramin, metabotropic P2Y receptor blocker reactive blue 2 and U73122, an inhibitor of phospholipase C. P2Y-mediated regulation is not coupled to presynaptic voltage-dependent Ca(2+) channels. During the simultaneous application of ATP and glutamate (which is another ACh cotransmitter reducing non-quantal release), the additive depressant effect led to a disappearance of the H-effect. This can be explained by the independence of the action of ATP and glutamate. Unlike the effects of purines on the spontaneous quantal secretion of ACh, its non-quantal release is regulated via P2Y receptors coupled to G(q/11) and PLC. ATP thus regulates the neuromuscular synapse by two different pathways.
Collapse
|
7
|
ATP and acetylcholine, equal brethren. Neurochem Int 2007; 52:634-48. [PMID: 18029057 DOI: 10.1016/j.neuint.2007.09.004] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2007] [Revised: 09/07/2007] [Accepted: 09/10/2007] [Indexed: 12/13/2022]
Abstract
Acetylcholine was the first neurotransmitter identified and ATP is the hitherto final compound added to the list of small molecule neurotransmitters. Despite the wealth of evidence assigning a signaling role to extracellular ATP and other nucleotides in neural and non-neural tissues, the significance of this signaling pathway was accepted very reluctantly. In view of this, this short commentary contrasts the principal molecular and functional components of the cholinergic signaling pathway with those of ATP and other nucleotides. It highlights pathways of their discovery and analyses tissue distribution, synthesis, uptake, vesicular storage, receptors, release, extracellular hydrolysis as well as pathophysiological significance. There are differences but also striking similarities. Comparable to ACh, ATP is taken up and stored in synaptic vesicles, released in a Ca(2+)-dependent manner, acts on nearby ligand-gated or metabotropic receptors and is hydrolyzed extracellularly. ATP and acetylcholine are also costored and coreleased. In addition, ATP is coreleased from biogenic amine storing nerve terminals as well as from at least subpopulations of glutamatergic and GABAergic terminals. Both ACh and ATP fulfill the criteria postulated for neurotransmitters. More recent evidence reveals that the two messengers are not confined to neural functions, exerting a considerable variety of non-neural functions in non-innervated tissues. While it has long been known that a substantial number of pathologies originate from malfunctions of the cholinergic system there is now ample evidence that numerous pathological conditions have a purinergic component.
Collapse
|